We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Has Agios Pharmaceuticals (AGIO) Outpaced Other Medical Stocks This Year?
Read MoreHide Full Article
Investors focused on the Medical space have likely heard of Agios Pharmaceuticals (AGIO - Free Report) , but is the stock performing well in comparison to the rest of its sector peers? A quick glance at the company's year-to-date performance in comparison to the rest of the Medical sector should help us answer this question.
Agios Pharmaceuticals is a member of the Medical sector. This group includes 888 individual stocks and currently holds a Zacks Sector Rank of #1. The Zacks Sector Rank includes 16 different groups and is listed in order from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors.
The Zacks Rank emphasizes earnings estimates and estimate revisions to find stocks with improving earnings outlooks. This system has a long record of success, and these stocks tend to be on track to beat the market over the next one to three months. AGIO is currently sporting a Zacks Rank of #2 (Buy).
Over the past 90 days, the Zacks Consensus Estimate for AGIO's full-year earnings has moved 29.36% higher. This is a sign of improving analyst sentiment and a positive earnings outlook trend.
According to our latest data, AGIO has moved about 8.40% on a year-to-date basis. Meanwhile, the Medical sector has returned an average of 0.21% on a year-to-date basis. This shows that Agios Pharmaceuticals is outperforming its peers so far this year.
To break things down more, AGIO belongs to the Medical - Products industry, a group that includes 81 individual companies and currently sits at #63 in the Zacks Industry Rank. On average, this group has lost an average of 5.07% so far this year, meaning that AGIO is performing better in terms of year-to-date returns.
Investors in the Medical sector will want to keep a close eye on AGIO as it attempts to continue its solid performance.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Has Agios Pharmaceuticals (AGIO) Outpaced Other Medical Stocks This Year?
Investors focused on the Medical space have likely heard of Agios Pharmaceuticals (AGIO - Free Report) , but is the stock performing well in comparison to the rest of its sector peers? A quick glance at the company's year-to-date performance in comparison to the rest of the Medical sector should help us answer this question.
Agios Pharmaceuticals is a member of the Medical sector. This group includes 888 individual stocks and currently holds a Zacks Sector Rank of #1. The Zacks Sector Rank includes 16 different groups and is listed in order from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors.
The Zacks Rank emphasizes earnings estimates and estimate revisions to find stocks with improving earnings outlooks. This system has a long record of success, and these stocks tend to be on track to beat the market over the next one to three months. AGIO is currently sporting a Zacks Rank of #2 (Buy).
Over the past 90 days, the Zacks Consensus Estimate for AGIO's full-year earnings has moved 29.36% higher. This is a sign of improving analyst sentiment and a positive earnings outlook trend.
According to our latest data, AGIO has moved about 8.40% on a year-to-date basis. Meanwhile, the Medical sector has returned an average of 0.21% on a year-to-date basis. This shows that Agios Pharmaceuticals is outperforming its peers so far this year.
To break things down more, AGIO belongs to the Medical - Products industry, a group that includes 81 individual companies and currently sits at #63 in the Zacks Industry Rank. On average, this group has lost an average of 5.07% so far this year, meaning that AGIO is performing better in terms of year-to-date returns.
Investors in the Medical sector will want to keep a close eye on AGIO as it attempts to continue its solid performance.